Literature DB >> 16368324

Immediate and late outcomes of patients undergoing transseptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases.

Tsun-Jui Liu1, Hui-Chin Lai, Wen-Lieng Lee, Kuo-Yang Wang, Tsu-Juey Wu, Jin-Long Huang, Chung-Whei Hsueh, Chih-Tai Ting.   

Abstract

BACKGROUND: The transseptal technique has been widely used for diagnostic and therapeutic left-sided heart catheterization. However, its differential immediate and late outcomes among patients with various valvular and arrhythmic diseases are not yet determined.
METHODS: Beginning from 1993, all patients undergoing transseptal procedures were screened and categorized into diagnosis, arrhythmia, and valvuloplasty groups according to the purposes of the catheterization. Incidences of transseptum-related acute major events (cardiac perforation, embolic stroke, and bradyarrhythmia during the procedure) and late complications (residual atrial septal defect [ASD], embolic stroke, bradyarrhythmia, and death up to 18 months) were analyzed and compared between groups.
RESULTS: From January 1993 to May 2003, a total of 176 patients underwent 184 transseptal procedures for diagnosis of valvular heart diseases (n = 8), catheter ablation of arrhythmogenic foci (n = 29), and mitral valvuloplasty (n = 147). The immediate outcome was similar among the 3 groups, with an overall acute complication incidence of 3.8%. At follow-up, the incidences of bradyarrhythmia, embolic stroke, and death were not different among the 3 groups. Patients undergoing valvuloplasty had a significantly higher prevalence of residual ASD, especially for those with more severe mitral stenosis and less valvuloplasty success. However, presence of ASD did not impose disadvantage over the 1.5-year prognosis.
CONCLUSION: Transseptal left-sided heart catheterization can be safely applied to patients with different categories of cardiac diseases with comparably good immediate and late outcomes. Although patients undergoing percutaneous valvuloplasty have a higher chance of permanent ASD creation, their prognosis is not influenced.

Entities:  

Mesh:

Year:  2006        PMID: 16368324     DOI: 10.1016/j.ahj.2005.02.034

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Direct transatrial pericardiocentesis for tamponade caused by left atrial perforation after trans-septal puncture.

Authors:  Fabien Picard; Xavier Millán; Quentin de Hemptinne; Philippe L L'allier
Journal:  BMJ Case Rep       Date:  2016-07-07

2.  Real-time MR imaging-guided laser atrial septal puncture in swine.

Authors:  Abdalla A Elagha; Ozgur Kocaturk; Michael A Guttman; Cengizhan Ozturk; Ann H Kim; George W Burton; June H Kim; Venkatesh K Raman; Amish N Raval; Victor J Wright; William H Schenke; Elliot R McVeigh; Robert J Lederman
Journal:  J Vasc Interv Radiol       Date:  2008-07-21       Impact factor: 3.464

3.  Percutaneous transseptal left atrial drainage for decompression of the left heart in an adult patient during percutaneous cardiopulmonary support.

Authors:  Min-Ho Kang; Joo-Yong Hahn; Hyeon-Cheol Gwon; Young Bin Song; Jin Oh Choi; Jin-Ho Choi; Seung-Hyuk Choi; Sang Hoon Lee; Eun Suk Jeon
Journal:  Korean Circ J       Date:  2011-07-30       Impact factor: 3.243

4.  Real Time 3D Echocardiographic Evaluation of Iatrogenic Atrial Septal Defects After Percutaneous Transvenous Mitral Commissurotomy.

Authors:  Sarath Babu Devarakonda; Boochi Babu Mannuva; Rajasekhar Durgaprasad; Vanajakshamma Velam; Vidya Sagar Akula; Latheef Kasala
Journal:  J Cardiovasc Thorac Res       Date:  2015

Review 5.  Haemodynamic and functional consequences of the iatrogenic atrial septal defect following Mitraclip therapy.

Authors:  E A Hart; K Zwart; A J Teske; M Voskuil; P R Stella; S A J Chamuleau; A O Kraaijeveld
Journal:  Neth Heart J       Date:  2017-02       Impact factor: 2.380

6.  Catheter ablation of a left free-wall accessory pathway via the radial artery approach.

Authors:  Dong Won Lee; Jun Kim; Han-Cheol Lee; June Hong Kim; Kook Jin Chun; Taek Jong Hong; Yung Woo Shin
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.